Immunotherapy in hepatocellular cancer.

Area of Science:

• Hepatology and Immunology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a significant global health issue, often linked to chronic liver inflammation and immune dysregulation.
• The liver's inherent immune tolerance can be exploited in HCC development, leading to T-cell exhaustion.
• Current immunotherapies, like PD-1 inhibitors, show limited efficacy in advanced HCC.

Purpose of the Study:

• To review current immunotherapy strategies for hepatocellular carcinoma.
• To discuss novel immunotherapy approaches for HCC treatment.
• To explore optimal patient selection for immunotherapy.

Main Methods:

• Review of existing literature on HCC immunotherapy.
• Analysis of clinical trial data for immune checkpoint inhibitors.
• Examination of emerging combinatorial strategies targeting HCC hallmarks.

Main Results:

• Immune checkpoint inhibitors targeting the PD-1 axis have shown some efficacy but benefit a subset of patients.
• Combinatorial therapies involving other immune checkpoint inhibitors are under investigation.
• Targeting the vascular endothelial growth factor (VEGF) axis alongside immunotherapy is a recent strategy.

Conclusions:

• Despite advances, most HCC patients do not respond to current monotherapy immunotherapies.
• Novel combinatorial approaches and improved patient selection are crucial for enhancing treatment efficacy.
• Further research into understanding HCC immune microenvironment is needed for developing next-generation therapies.